title: Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest risk.
abstract: OBJECTIVE
  To evaluate a sensor-augmented insulin pump with a low glucose suspend (LGS) feature that automatically suspends basal insulin delivery for up to 2 h in response to sensor-detected hypoglycemia.
  
  
  METHODS
  The LGS feature of the Paradigm Veo insulin pump (Medtronic, Inc., Northridge, CA) was tested for 3 weeks in 31 adults with type 1 diabetes.
  
  
  RESULTS
  There were 166 episodes of LGS: 66% of daytime LGS episodes were terminated within 10 min, and 20 episodes lasted the maximum 2 h. LGS use was associated with reduced nocturnal duration ≤2.2 mmol/L in those in the highest quartile of nocturnal hypoglycemia at baseline (median 46.2 vs. 1.8 min/day, P = 0.02 [LGS-OFF vs. LGS-ON]). Median sensor glucose was 3.9 mmol/L after 2-h LGS and 8.2 mmol/L at 2 h after basal restart.
  
  
  CONCLUSIONS
  Use of an insulin pump with LGS was associated with reduced nocturnal hypoglycemia in those at greatest risk and was well accepted by patients.
authors.affiliation: Department of Diabetes, King's College London School of Medicine, London, UK. pratik.choudhary@kcl.ac.uk
authors.forename: Pratik
authors.initials: P
authors.lastname: Choudhary
authors.forename: John
authors.initials: J
authors.lastname: Shin
authors.forename: Yongyin
authors.initials: Y
authors.lastname: Wang
authors.forename: Mark L
authors.initials: ML
authors.lastname: Evans
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Hammond
authors.forename: David
authors.initials: D
authors.lastname: Kerr
authors.forename: James A M
authors.initials: JA
authors.lastname: Shaw
authors.forename: John C
authors.initials: JC
authors.lastname: Pickup
authors.forename: Stephanie A
authors.initials: SA
authors.lastname: Amiel
mesh_terms: D000328:Adult; D002940:Circadian Rhythm / Q000502:physiology; D005260:Female; D006801:Humans; D007003:Hypoglycemia / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D007328:Insulin / Q000008:administration & dosage* / Q000627:therapeutic use*; D007332:Insulin Infusion Systems; D008297:Male; D008875:Middle Aged
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin